<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7536086\results\search\disease\results.xml">
  <result pre="100120031: Review: Review Article Convalescent plasma therapy: a promising coronavirus" exact="disease" post="2019 treatment strategy Plasma therapy a possible hope to"/>
  <result pre="28A, Furshatpur, Motihari, Bihar 845401India[4], Department of Biotechnology, Mahatma Gandhi" exact="Central" post="UniversityMotihari 845401India e-mail: khanrajni@gmail.com e-mail: shashikantray@mgcub.ac.in â€ These authors"/>
  <result pre="passing through a very difficult phase due to the coronavirus" exact="disease" post="2019 (COVID-19) pandemic, which has disrupted almost all spheres"/>
  <result pre="lack of specific therapeutic drugs and vaccines, the outbreak of" exact="disease" post="has spawned a corpus of contagious infection all over"/>
  <result pre="the outbreak of disease has spawned a corpus of contagious" exact="infection" post="all over the world, day by day, without control."/>
  <result pre="the world, day by day, without control. As the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid"/>
  <result pre="world, day by day, without control. As the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) has a very rapid infection"/>
  <result pre="day by day, without control. As the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) has a very rapid infection rate,"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid" exact="infection" post="rate, it is essential to develop a novel ameliorative"/>
  <result pre="has already been found to be effective in confronting several" exact="infectious diseases" post="from the last two decades. For example, CP therapy"/>
  <result pre="the treatment of viral-induced diseases like SARS-CoV epidemics, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic."/>
  <result pre="treatment of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic. In"/>
  <result pre="Wuhan, Hubei province of China, in November 2019 [1]. The" exact="disease" post="remained asymptomatic in its initial stages of infection, and"/>
  <result pre="due to the mild symptoms. As the severity of the" exact="disease" post="increased in the following days, and the number of"/>
  <result pre="the following days, and the number of people suffering from" exact="respiratory" post="tract infections escalated, soon it became a matter of"/>
  <result pre="days, and the number of people suffering from respiratory tract" exact="infections" post="escalated, soon it became a matter of global concern"/>
  <result pre="international emergency [4]. Later, the phylogenetic analysis of the novel" exact="viral" post="genome revealed that it shared 89.1% similarity to the"/>
  <result pre="genome revealed that it shared 89.1% similarity to the severe" exact="acute" post="respiratory syndrome (SARS) coronaviruses, and consists of 29 903"/>
  <result pre="revealed that it shared 89.1% similarity to the severe acute" exact="respiratory" post="syndrome (SARS) coronaviruses, and consists of 29 903 nucleotides"/>
  <result pre="that it shared 89.1% similarity to the severe acute respiratory" exact="syndrome" post="(SARS) coronaviruses, and consists of 29 903 nucleotides which"/>
  <result pre="WHO abbreviated the novel coronavirus as SARS-CoV-2, and the new" exact="disease" post="coronavirus disease 2019 as COVID-19 [4]. Coronaviruses (CoVs) belong"/>
  <result pre="the novel coronavirus as SARS-CoV-2, and the new disease coronavirus" exact="disease" post="2019 as COVID-19 [4]. Coronaviruses (CoVs) belong to the"/>
  <result pre="coronavirus family in humans [8]. SARS-CoV and MERS-CoV (Middle East" exact="respiratory" post="syndrome coronavirus) both belong to the Î²-coronavirus subfamily, like"/>
  <result pre="family in humans [8]. SARS-CoV and MERS-CoV (Middle East respiratory" exact="syndrome" post="coronavirus) both belong to the Î²-coronavirus subfamily, like the"/>
  <result pre="is still struggling to develop a potent vaccine to prevent" exact="infection" post="[14]. Presently, the management of SARS-CoV-2-infected patients basically emphasizes"/>
  <result pre="by several countries to treat patients suffering from severe SARS-CoV-2" exact="infection" post="[18,19]. CP has proved its effectiveness in neutralizing viruses"/>
  <result pre="the human angiotensin-converting enzyme 2 (hACE2) receptors present on the" exact="epithelial" post="surface of several organs like lungs, heart, kidney, brain"/>
  <result pre="the epithelial surface of several organs like lungs, heart, kidney," exact="brain" post="and small intestine, and thereby several organs are found"/>
  <result pre="the interleukin-6 amplifier (IL-6 Amp), resulting in multiple inflammatory and" exact="autoimmune diseases" post="[28]. Interestingly, the exposure of SARS-CoV-2 does not infect"/>
  <result pre="the entire population, and not all infected persons acquire severe" exact="respiratory" post="illness. This differential infection and illness may depend upon"/>
  <result pre="not all infected persons acquire severe respiratory illness. This differential" exact="infection" post="and illness may depend upon the immune response of"/>
  <result pre="response of individuals. Based on the differential response, the SARS-CoV-2" exact="infection" post="is clinically categorized into mainly two stages [16]: non-severe"/>
  <result pre="stages [16]: non-severe and severe. 1.1.1. Non-severe stage To prevent" exact="infection" post="at an initial stage, a specific adaptive immune response"/>
  <result pre="a specific adaptive immune response is needed to stop the" exact="disease" post="progression. So, several immune booster food supplements and vitamins"/>
  <result pre="and vitamins have been recommended to enhance immunity [16]. The" exact="disease" post="progression varies depending on the genetic composition of the"/>
  <result pre="background, the immune system of individuals responds differently to the" exact="infection" post="[29]. 1.1.2. Severe stage This is also known as"/>
  <result pre="system of individuals responds differently to the infection [29]. 1.1.2." exact="Severe" post="stage This is also known as a severe respiratory"/>
  <result pre="1.1.2. Severe stage This is also known as a severe" exact="respiratory" post="symptomatic stage with high viral load. In this stage,"/>
  <result pre="Severe stage This is also known as a severe respiratory" exact="symptomatic" post="stage with high viral load. In this stage, the"/>
  <result pre="also known as a severe respiratory symptomatic stage with high" exact="viral" post="load. In this stage, the virus is able to"/>
  <result pre="In the severe stage, the main cause of the fatal" exact="respiratory" post="ailments is inflammation in the lungs [31]. 2. The"/>
  <result pre="of passive antibody therapy In order to treat or prevent" exact="infection" post="of particular diseases, the susceptible individual is administered with"/>
  <result pre="active immune response develops against any diseases either due to" exact="infection" post="from a pathogen or due to the administration of"/>
  <result pre="or due to the administration of specific vaccine against the" exact="disease" post="that triggers the immune response. The active immune response"/>
  <result pre="technique to provide immediate immunity to vulnerable individuals in a" exact="short" post="span of time. The passive antibody therapeutic strategy dates"/>
  <result pre="in 1901 [37]. Furthermore, Behring and Shibasaburo Kitasato reported that" exact="tetanus" post="in rabbits could be prevented by immunizing the rabbit"/>
  <result pre="rabbits could be prevented by immunizing the rabbit serum with" exact="tetanus" post="toxin priorly [38]. The basic principle involved in passive"/>
  <result pre="to be very much smaller than that of the prevailing" exact="disease" post="[39]. According to another interpretation, the antibody works via"/>
  <result pre="proposed in the nineteenth century when it showed immunity against" exact="diphtheria" post="[41]. The existing antibodies in the blood derived from"/>
  <result pre="the recipient to avoid the inflammatory cascade triggered by various" exact="infectious" post="agents [44,45]. The purification and concentration of immunoglobulins from"/>
  <result pre="donors in the 1950s provided an alternative to treat severely" exact="infectious" post="ailments as well as compromised immune conditions including allergies,"/>
  <result pre="infectious ailments as well as compromised immune conditions including allergies," exact="autoimmune diseases" post="and primary immunodeficiencies [43,46,47]. Be it the current pandemic"/>
  <result pre="well as compromised immune conditions including allergies, autoimmune diseases and" exact="primary" post="immunodeficiencies [43,46,47]. Be it the current pandemic caused by"/>
  <result pre="in view the usage of mechanized ventilation systems during the" exact="avian influenza" post="A (H5N1) and the 2009 pandemic of influenza A"/>
  <result pre="improvement in their clinical condition and a reduction of the" exact="viral" post="load [53,54]. Intravenous immunoglobulins (IVIg), monoclonal or polyclonal antibodies,"/>
  <result pre="other convalescent blood products have been developed to deal with" exact="infectious" post="indispositions [55]. Despite this fact, they may not yield"/>
  <result pre="indispositions [55]. Despite this fact, they may not yield appropriate" exact="infection" post="control and are quite difficult and expensive to produce."/>
  <result pre="CP therapy has been used to prevent and treat several" exact="infectious diseases" post="for more than one century and is one of"/>
  <result pre="the meta-analysis of 32 different studies focusing on severe influenza" exact="infections" post="and SARS-CoV infections statistically suggested that a significant reduction"/>
  <result pre="32 different studies focusing on severe influenza infections and SARS-CoV" exact="infections" post="statistically suggested that a significant reduction was observed in"/>
  <result pre="via passive antibody therapy, and in combination with antiviral drugs," exact="viral" post="neutralization can be achieved [32]. The duration of therapy"/>
  <result pre="serum mainly depend on the severity of COVID-19 and the" exact="viral" post="load [62]. For treating or preventing the initial symptoms"/>
  <result pre="in small amounts are considered to be effective. Individuals having" exact="chronic" post="underlying diseases, healthy individuals who have been in contact"/>
  <result pre="COVID-19 negative after 14 days and should not display any" exact="infective" post="symptoms. These tests must be conducted again after 48"/>
  <result pre="molecular evaluations, it is also very important to identify the" exact="emotional" post="conditions of the donor in order to ensure they"/>
  <result pre="potency [67]. Conduction of medical examinations and clinical evaluation for" exact="hepatitis" post="B and C, human immunodeficiency virus (HIV), human T-cell"/>
  <result pre="examinations and clinical evaluation for hepatitis B and C, human" exact="immunodeficiency" post="virus (HIV), human T-cell lymphotropic virus types 1 and"/>
  <result pre="and C, human immunodeficiency virus (HIV), human T-cell lymphotropic virus" exact="types 1 and 2," post="Trypanosoma cruzi (if residing in an endemic area) and"/>
  <result pre="2, Trypanosoma cruzi (if residing in an endemic area) and" exact="syphilis" post="are essential as high-quality standards are required in CP"/>
  <result pre="required in CP production, and it should be free from" exact="infections" post="of any sort [65,68]. Therefore, in order to assure"/>
  <result pre="compulsory to perform a nucleic acid test for HIV and" exact="hepatitis" post="viruses [69]. Neutralization of pathogens with UV light exposure"/>
  <result pre="Neutralizing antibodies play a crucial role in the elimination of" exact="viral infection" post="and are believed to be essential in prevention from"/>
  <result pre="antibodies play a crucial role in the elimination of viral" exact="infection" post="and are believed to be essential in prevention from"/>
  <result pre="infection and are believed to be essential in prevention from" exact="viral" post="illnesses [71]. Neutralizing antibodies that prevent these infections are"/>
  <result pre="prevention from viral illnesses [71]. Neutralizing antibodies that prevent these" exact="infections" post="are provided by passive immunity, impelled by CP. The"/>
  <result pre="SARS-CoV, it was found that the neutralizing antibodies inhibit the" exact="viral" post="amplification by binding to the N-terminal domain of S1,"/>
  <result pre="domains of S protein, and thereby help in controlling the" exact="infection" post="[74]. Furthermore, CP administration is also known to enhance"/>
  <result pre="day or on the 4th day after the beginning of" exact="disease" post="[75]. Even after 2 years of SARS-CoV infection, around"/>
  <result pre="promote prophylaxis [67], but it did not intervene in the" exact="viral" post="replication. FigureÂ 1 briefly describes the mechanism of CP"/>
  <result pre="CP therapy In various studies, it has been shown that" exact="viral" post="infections in the blood, such as SARS-CoV infection, are"/>
  <result pre="therapy In various studies, it has been shown that viral" exact="infections" post="in the blood, such as SARS-CoV infection, are at"/>
  <result pre="are at their maximum during the first week of the" exact="infection" post="[56]. After the onset of symptoms in the second"/>
  <result pre="known risks include reactions against the plasma constituents and unintended" exact="infections" post="induced by several infectious agents that might be present"/>
  <result pre="against the plasma constituents and unintended infections induced by several" exact="infectious" post="agents that might be present in the serum [32]."/>
  <result pre="antibody-dependent enhancement of infection, in which the severity of a" exact="viral" post="disease is enhanced in the presence of specific antibodies"/>
  <result pre="enhancement of infection, in which the severity of a viral" exact="disease" post="is enhanced in the presence of specific antibodies [32]."/>
  <result pre="fevers, anaphylactic reactions, chills, transfusion-associated circulatory overload, haemolysis and transfusion-related" exact="acute" post="lung injuries (TRALIs) [79]. At the same time, HIV,"/>
  <result pre="lung injuries (TRALIs) [79]. At the same time, HIV, syphilis," exact="hepatitis" post="B and C, and various other transfusion-mediated infections should"/>
  <result pre="HIV, syphilis, hepatitis B and C, and various other transfusion-mediated" exact="infections" post="should also not be neglected [80â€&quot;82]. In the case"/>
  <result pre="case of developing and populous countries like India, if the" exact="disease" post="spreads at a rapid rate and the infected persons"/>
  <result pre="patients [83]. 6. Accomplishments using CP therapy Due to the" exact="absence of" post="any specified treatment for COVID-19, researchers are still searching"/>
  <result pre="the efficacy of CP therapy in curing patients with SARS-CoV-2" exact="infection" post="[54,85,86]. TableÂ 1 precisely enlists the CP administration in"/>
  <result pre="during previously encountered coronavirus outbreaks along with the novel coronavirus." exact="disease" post="and the causative agent CP dose (volume) antibody titre"/>
  <result pre="severely affected patients who were confirmed positive in a real-time" exact="viral" post="RNA test. The patients were administered with a single"/>
  <result pre="to 18.3 mg lâˆ’1 was also observed along with the" exact="chest" post="computerized tomography (CT) scans revealing a reduction in the"/>
  <result pre="chest computerized tomography (CT) scans revealing a reduction in the" exact="pulmonary" post="lesions. The study reported no severe unpropitious effects, and"/>
  <result pre="clinical outcomes by neutralizing viraemia in patients with critical SARS-CoV-2" exact="infection" post="and can serve as a promising rescue option for"/>
  <result pre="sick patients of SARS-CoV-2 infection, who were suffering from critical" exact="respiratory" post="ailments. The patients were subjected to transfusion with CP,"/>
  <result pre="therapy. The study entitled â€˜Convalescent Plasma as Therapy for COVID-19" exact="Severe" post="SARS-CoV-2 Disease (CONCOVID Study)â€™ (clinical trial no. NCT04342182) is"/>
  <result pre="study entitled â€˜Convalescent Plasma as Therapy for COVID-19 Severe SARS-CoV-2" exact="Disease" post="(CONCOVID Study)â€™ (clinical trial no. NCT04342182) is a randomized"/>
  <result pre="safety of CP from COVID-recovered donors as a cure for" exact="symptomatic" post="patients of COVID-19 in the hospital. In another study"/>
  <result pre="Transfusion of Convalescent Plasma in Elderly COVID-19 Patients to Prevent" exact="Disease" post="Progressionâ€™ (clinical trial no. NCT04374526), the investigators hypothesize that"/>
  <result pre="comprising the neutralizing antibodies, at an early stage of COVID-19" exact="infection" post="can prevent the inflammatory response induced by SARS-CoV-2. The"/>
  <result pre="The main objectives of this trial include the prevention of" exact="pneumonia" post="progression in elderly COVID-19 patients (more than 65 years"/>
  <result pre="age), raising anti-SARS-CoV-2 antibody titres in recipients and decreasing the" exact="viral" post="load using the CP therapy, along with standard therapy."/>
  <result pre="CP with an antibody against SARS-CoV-2 in COVID-19 patients with" exact="pneumonia" post="and hypoxia and to find out whether there is"/>
  <result pre="an antibody against SARS-CoV-2 in COVID-19 patients with pneumonia and" exact="hypoxia" post="and to find out whether there is any improvement"/>
  <result pre="a high-risk population that has viraemia before they develop any" exact="pulmonary" post="infection/injury and start relying on supplementary oxygen therapy. 8."/>
  <result pre="as an immediate therapeutic to control the disease, in the" exact="absence of" post="appropriate drugs or vaccine. Since CP therapy has been"/>
  <result pre="been a prevalent and effective mode of treatment in various" exact="viral" post="infections in the past (e.g. Ebola, MERS and SARS-CoV"/>
  <result pre="a prevalent and effective mode of treatment in various viral" exact="infections" post="in the past (e.g. Ebola, MERS and SARS-CoV [84]),"/>
  <result pre="already played an important role in the therapy of several" exact="viral" post="diseases. In the case of COVID-19, to date, this"/>
  <result pre="Kamaraj University, Madurai, Tamil Nadu, IIEST, Shibpur, and Mahatma Gandhi" exact="Central" post="University Motihari, Bihar, respectively. We thank Aroni Chatterjee for"/>
  <result pre="study. References References 1ZhuNet al.2020A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl. J. Med.382, 727â€&quot;733. (10.1056/NEJMoa2001017)31978945"/>
  <result pre="Indian J. Pediatr.87, 281â€&quot;286. (10.1007/s12098-020-03263-6)32166607 3collab: World Health Organization. 2020Coronavirus" exact="disease" post="(COVID-19) pandemic. See https://www.who.int/emergencies/diseases/novel-coronavirus-2019. 4RajarshiK, ChatterjeeA, RayS2020Combating COVID-19 with"/>
  <result pre="Biotechnol. Rep.26, e00467. 5WuFet al.2020A new coronavirus associated with human" exact="respiratory" post="disease in China. Nature579, 265â€&quot;269. (10.1038/s41586-020-2008-3)32015508 6RajarshiK, ChatterjeeA, RayS2020BCG"/>
  <result pre="Rep.26, e00467. 5WuFet al.2020A new coronavirus associated with human respiratory" exact="disease" post="in China. Nature579, 265â€&quot;269. (10.1038/s41586-020-2008-3)32015508 6RajarshiK, ChatterjeeA, RayS2020BCG vaccination"/>
  <result pre="or Hope?Med. Drug Discov.7, 100049.32835211 7LiH, LiuSM, YuXH, TangSL, TangCK2020Coronavirus" exact="disease" post="2019 (COVID-19): current status and future perspectives. Int. J."/>
  <result pre="Int. J. Biol. Sci.16, 1686â€&quot;1697. (10.7150/ijbs.45472)32226286 11ZumlaA, HuiDS, PerlmanS2015Middle East" exact="respiratory" post="syndrome. The Lancet386, 995â€&quot;1007. (10.1016/S0140-6736(15)60454-8) 12KimD, LeeJ-Y, YangJ-S, KimJW,"/>
  <result pre="914â€&quot;921. e10. (10.1016/j.cell.2020.04.011)32330414 13ShangW, YangY, RaoY, RaoX2020The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccines. npj Vaccines5, 1â€&quot;3. (10.1038/s41541-020-0170-0)31908850 14El-Aziz"/>
  <result pre="13ShangW, YangY, RaoY, RaoX2020The outbreak of SARS-CoV-2 pneumonia calls for" exact="viral" post="vaccines. npj Vaccines5, 1â€&quot;3. (10.1038/s41541-020-0170-0)31908850 14El-Aziz TMA, StockandJD2020Recent progress"/>
  <result pre="Differ.27, 1451â€&quot;1454. (10.1038/s41418-020-0530-3)32205856 17JayawardenaR, SooriyaarachchiP, ChourdakisM, JeewandaraC, RanasinghePJD2020Enhancing immunity in" exact="viral" post="infections, with special emphasis on COVID-19: a reviewDiabetes &amp;amp;"/>
  <result pre="Poverty9, 1â€&quot;7. (10.1186/s40249-020-00662-x)31996251 31XuZet al.2020Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir. Med.8, 420â€&quot;422. (10.1016/S2213-2600(20)30076-X)32085846 32CasadevallA,"/>
  <result pre="1â€&quot;7. (10.1186/s40249-020-00662-x)31996251 31XuZet al.2020Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir. Med.8, 420â€&quot;422. (10.1016/S2213-2600(20)30076-X)32085846 32CasadevallA, PirofskiLA2020The"/>
  <result pre="Invest.130, 1545â€&quot;1548. (10.1172/JCI138003)32167489 33SawyerL2000Antibodies for the prevention and treatment of" exact="viral" post="diseases. Antiviral Res.47, 57â€&quot;77. (10.1016/s0166-3542(00)00111-x)10996394 34ClemAS2011Fundamentals of vaccine immunology."/>
  <result pre="ScharffMD1995Return to the past: the case for antibody-based therapies in" exact="infectious diseases." post="Clin. Infect. Dis.21, 150â€&quot;161. (10.1093/clinids/21.1.150)7578724 36CasadevallA, DadachovaE, PirofskiLA2004Passive antibody"/>
  <result pre="Infect. Dis.21, 150â€&quot;161. (10.1093/clinids/21.1.150)7578724 36CasadevallA, DadachovaE, PirofskiLA2004Passive antibody therapy for" exact="infectious diseases." post="Nat. Rev. Microbiol.2, 695â€&quot;703. (10.1038/nrmicro974)15372080 37WinauF, WinauRJM2002Emil von Behring"/>
  <result pre="hypothesis: serum IgG antibody is sufficient to confer protection against" exact="infectious diseases" post="by inactivating the inoculum. J. Infect. Dis.171, 1387â€&quot;1398. (10.1093/infdis/171.6.1387)7769272"/>
  <result pre="44ShakirEM, CheungDS, GraysonMH2010Mechanisms of immunotherapy: a historical perspective. Ann. Allergy" exact="Asthma" post="Immunol.105, 340â€&quot;347. (10.1016/j.anai.2010.09.012)21055659 45GarraudO, HeshmatiF, PozzettoB, LefrereF, GirotR, SaillolA,"/>
  <result pre="(10.1016/j.anai.2010.09.012)21055659 45GarraudO, HeshmatiF, PozzettoB, LefrereF, GirotR, SaillolA, LapercheS2016Plasma therapy against" exact="infectious" post="pathogens, as of yesterday, today and tomorrow. Transfus. Clin."/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysis."/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysis. J. Infect."/>
  <result pre="80â€&quot;90. (10.1093/infdis/jiu396)25030060 49YehK-Met al.2005Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospital."/>
  <result pre="(10.1093/infdis/jiu396)25030060 49YehK-Met al.2005Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital. J."/>
  <result pre="49YehK-Met al.2005Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital. J. Antimicrob."/>
  <result pre="J. Antimicrob. Chemother.56, 919â€&quot;922. (10.1093/jac/dki346)16183666 50WongSS, YuenK-Y2008The management of coronavirus" exact="infections" post="with particular reference to SARS. J. Antimicrob. Chemother.62, 437â€&quot;441."/>
  <result pre="and therapeutic experience of case of severe highly pathogenic A/H5N1" exact="avian influenza" post="with bronchopleural fistula. Chin. J. Tubercul. Respir. Dis.32, 356â€&quot;359."/>
  <result pre="al.2011Convalescent plasma treatment reduced mortality in patients with severe pandemic" exact="Influenza A (H1N1)" post="2009 virus infection. Clin. Infect. Dis.52, 447â€&quot;456. (10.1093/cid/ciq106)21248066 59KoJ-Het"/>
  <result pre="mortality in patients with severe pandemic Influenza A (H1N1) 2009" exact="virus infection." post="Clin. Infect. Dis.52, 447â€&quot;456. (10.1093/cid/ciq106)21248066 59KoJ-Het al.2018Challenges of convalescent"/>
  <result pre="59KoJ-Het al.2018Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experience. Antiviral Ther.23, 617â€&quot;622."/>
  <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
  <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
  <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysis."/>
  <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysis. J. Infect."/>
  <result pre="(10.1056/NEJMe2002387)32109011 62GasparyanAY, MisraDP, YessirkepovM, ZimbaO2020Perspectives of immune therapy in coronavirus" exact="disease" post="2019. J. Korean Med. Sci.35, e176 (10.3346/jkms.2020.35.e176)32383371 63BenjaminRJ, McLaughlinLS2012Plasma"/>
  <result pre="press.Screening blood donors for HIV, HCV and HBV at the" exact="American" post="Red Cross: ten-year trends in prevalence, incidence and residual"/>
  <result pre="the American Red Cross: ten-year trends in prevalence, incidence and" exact="residual" post="risk, 2007â€&quot;2016. Transf. Med. Rev. (10.1016/j.tmrv.2020.02.001) 69NiaziSK, BhattiFA, SalamatN,"/>
  <result pre="concentrates and plasma with riboflavin and UV light: impact in" exact="bacterial" post="reduction. Transf. Clin. Biol.25, 197â€&quot;203. (10.1016/j.tracli.2018.03.004) 71MurinCD, WilsonIA, WardAB2019Antibody"/>
  <result pre="Transf. Clin. Biol.25, 197â€&quot;203. (10.1016/j.tracli.2018.03.004) 71MurinCD, WilsonIA, WardAB2019Antibody responses to" exact="viral" post="infections: a structural perspective across three different enveloped viruses."/>
  <result pre="(10.1038/s41564-019-0392-y)30886356 72Van GriensvenJet al.2016Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in Guinea. N. Engl. J. Med.374, 33â€&quot;42. (10.1056/NEJMoa1511812)26735992 73RajendranK,"/>
  <result pre="YangP-C2004Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirus. Clin. Microbiol. Infect.10, 1062â€&quot;1066. (10.1111/j.1469-0691.2004.01009.x)15606632 76GorseGJ,"/>
  <result pre="antibody. Emerg. Microb. Infect.9, 382â€&quot;385. (10.1080/22221751.2020.1729069) 78PeirisJSMet al.2003Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
  <result pre="blood or plasma collected from patients recovered from Ebola virus" exact="disease" post="for transfusion, as an empirical treatment during outbreaks: interim"/>
  <result pre="Med. Virol.77, 147â€&quot;150. (10.1002/jmv.20431)16121363 88WongV, DaiD, WuA, SungJJ2003Treatment of severe" exact="acute" post="respiratory syndrome with convalescent plasma. Hong Kong Med. J.9,"/>
  <result pre="Virol.77, 147â€&quot;150. (10.1002/jmv.20431)16121363 88WongV, DaiD, WuA, SungJJ2003Treatment of severe acute" exact="respiratory" post="syndrome with convalescent plasma. Hong Kong Med. J.9, 199â€&quot;201.12777656"/>
  <result pre="147â€&quot;150. (10.1002/jmv.20431)16121363 88WongV, DaiD, WuA, SungJJ2003Treatment of severe acute respiratory" exact="syndrome" post="with convalescent plasma. Hong Kong Med. J.9, 199â€&quot;201.12777656 89KongLJT2003Severe"/>
  <result pre="syndrome with convalescent plasma. Hong Kong Med. J.9, 199â€&quot;201.12777656 89KongLJT2003Severe" exact="acute" post="respiratory syndrome (SARS). Transfus. Apher. Sci.29, 101 (10.1016/s1473-0502(03)00109-5)12952008 90KoJ-Het"/>
  <result pre="with convalescent plasma. Hong Kong Med. J.9, 199â€&quot;201.12777656 89KongLJT2003Severe acute" exact="respiratory" post="syndrome (SARS). Transfus. Apher. Sci.29, 101 (10.1016/s1473-0502(03)00109-5)12952008 90KoJ-Het al.2017Serologic"/>
  <result pre="convalescent plasma. Hong Kong Med. J.9, 199â€&quot;201.12777656 89KongLJT2003Severe acute respiratory" exact="syndrome" post="(SARS). Transfus. Apher. Sci.29, 101 (10.1016/s1473-0502(03)00109-5)12952008 90KoJ-Het al.2017Serologic responses"/>
  <result pre="90KoJ-Het al.2017Serologic responses of 42 MERS-coronavirus-infected patients according to the" exact="disease" post="severity. Diagn. Microbiol. Infect. Dis.89, 106â€&quot;111. (10.1016/j.diagmicrobio.2017.07.006)28821364 91ArabiYMet al.2016Feasibility"/>
  <result pre="92ChunS, ChungCR, HaYE, HanTH, KiC-S, KangE-S, ParkJK, PeckKR, ChoD2016Possible transfusion-related" exact="acute" post="lung injury following convalescent plasma transfusion in a patient"/>
  <result pre="following convalescent plasma transfusion in a patient with Middle East" exact="respiratory" post="syndrome. Ann. Lab. Med.36, 393â€&quot;395. (10.3343/alm.2016.36.4.393)27139619 93GuptaSS, GuptaAK, ChandakP,"/>
 </snippets>
</snippetsTree>
